Q2 revenue grew 43% year-over-year, driven by Afrezza pediatric launch and FUROSCIX growth. ReadyFlow approval and strong nintedanib DPI data position the company for continued momentum, with guidance reaffirmed and margin expansion expected in 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.